Fatty acid synthase ( FASN ) signalome: A molecular guide for precision oncology
Molecular Oncology · 2024-03 · 18 (3) · 479-516
DOI: 10.1002/1878-0261.13582 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 18.01.2024. Verfasst von Javier A Menendez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Metabolism & Cancer Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Girona, Spain. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 404 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, European Research Council, Ministerio de Economía y Competitividad.
Abstract (Originalsprache)
The initial excitement generated more than two decades ago by the discovery of drugs targeting fatty acid synthase (FASN)‐catalyzed de novo lipogenesis for cancer therapy was short‐lived. However, the advent of the first clinical‐grade FASN inhibitor (TVB‐2640; denifanstat), which is currently being studied in various phase II trials, and the exciting advances in understanding the FASN signalome are fueling a renewed interest in FASN‐targeted strategies for the treatment and prevention of cancer. Here, we provide a detailed overview of how FASN can drive phenotypic plasticity and cell fate decisions, mitochondrial regulation of cell death, immune escape and organ‐specific metastatic potential. We then present a variety of FASN‐targeted therapeutic approaches that address the major challenges facing FASN therapy. These include limitations of current FASN inhibitors and the lack of precision tools to maximize the therapeutic potential of FASN inhibitors in the clinic. Rethinking the role of FASN as a signal transducer in cancer pathogenesis may provide molecularly driven strategies to optimize FASN as a long‐awaited target for cancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolism & Cancer Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Girona, Spain.
- Girona Biomedical Research Institute, Girona, Spain.
- Institute of Research, Development and Innovation in Biotechnology of Elche (IDiBE) and Molecular and Cell Biology Institute (IBMC), Miguel Hernández University (UMH), Elche, Spain.
- Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
- Mayo Clinic Cancer Center, Rochester, MN, USA.
- Department of Biochemistry and Molecular Biology Laboratory, Mayo Clinic Laboratory, Rochester, MN, USA.
ORCID-Profile: Javier A Menendez
Förderung
- NCI NIH HHS
- European Research Council
- Ministerio de Economía y Competitividad
- Ministerio de Ciencia e Innovación
- Generalitat Valenciana
- Instituto de Salud Carlos III
- Human Frontier Science Program
Zitieren
APA
Menendez, J. A., Cuyàs, E., Encinar, J. A., Vander Steen, T., Verdura, S., Llop-Hernández, À., López, J., Serrano-Hervás, E., Osuna, S., Martin-Castillo, B., & Lupu, R. (2024). Fatty acid synthase ( FASN ) signalome: A molecular guide for precision oncology. Molecular Oncology, 18(3), 479-516. https://doi.org/10.1002/1878-0261.13582
Vancouver
Menendez JA, Cuyàs E, Encinar JA, Vander Steen T, Verdura S, Llop-Hernández À, et al. Fatty acid synthase ( FASN ) signalome: A molecular guide for precision oncology. Molecular Oncology. 2024;18(3):479-516. doi:10.1002/1878-0261.13582
BibTeX
@article{Menendez2024,
author = {Menendez, Javier A and Cuyàs, Elisabet and Encinar, Jose Antonio and Vander Steen, Travis and Verdura, Sara and Llop-Hernández, Àngela and López, Júlia and Serrano-Hervás, Eila and Osuna, Sílvia and Martin-Castillo, Begoña and Lupu, Ruth},
title = {Fatty acid synthase ( FASN ) signalome: A molecular guide for precision oncology},
journal = {Molecular Oncology},
year = {2024},
volume = {18},
number = {3},
pages = {479--516},
doi = {10.1002/1878-0261.13582}
}
EUVIMED